Mimedx (MDXG) Current Assets (2010 - 2026)
Mimedx recorded quarterly Current Assets of $240.3 million in Q1 2026, down 13.39% quarter-over-quarter from $277.5 million in Q4 2025, and up 20.1% year-over-year from $200.1 million in Q1 2025.
Mimedx's Current Assets history runs 17 years deep, the most recent figure standing at $240.3 million for Q1 2026.
- In Q1 2026, Current Assets rose 20.1% year-over-year to $240.3 million; the TTM figure through Mar 2026 stood at $240.3 million (up 20.1% YoY), while the FY2025 annual figure was $277.5 million, up 44.6% from the prior year.
- Current Assets came in at $240.3 million for Q1 2026 at Mimedx, down from $277.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $277.5 million in Q4 2025 to a low of $131.0 million in Q2 2022.
- A 5-year average of $175.2 million and a median of $154.5 million in 2023 frame the typical range for Current Assets.
- Across the five-year window, Current Assets slipped 11.3% in 2022 and surged 47.61% in 2025, its largest moves.
- Mimedx's Current Assets stood at $134.2 million in 2022, then gained by 22.4% to $164.3 million in 2023, then grew by 16.82% to $191.9 million in 2024, then soared by 44.6% to $277.5 million in 2025, then retreated by 13.39% to $240.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $240.3 million, $277.5 million, and $254.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 240.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 240.33 Mn |
| Dec 31, 2025 | 277.47 Mn |
| Sep 30, 2025 | 254.10 Mn |
| Jun 30, 2025 | 220.88 Mn |
| Mar 31, 2025 | 200.11 Mn |
| Dec 31, 2024 | 191.89 Mn |
| Sep 30, 2024 | 172.14 Mn |
| Jun 30, 2024 | 154.02 Mn |
| Mar 31, 2024 | 138.85 Mn |
| Dec 31, 2023 | 164.26 Mn |
| Sep 30, 2023 | 154.50 Mn |
| Jun 30, 2023 | 141.22 Mn |
| Mar 31, 2023 | 131.70 Mn |
| Dec 31, 2022 | 134.20 Mn |
| Sep 30, 2022 | 136.04 Mn |
| Jun 30, 2022 | 131.01 Mn |
| Mar 31, 2022 | 135.91 Mn |
| Dec 31, 2021 | 148.52 Mn |
| Sep 30, 2021 | 141.90 Mn |
| Jun 30, 2021 | 147.69 Mn |
| Mar 31, 2021 | 149.96 Mn |
| Dec 31, 2020 | 160.62 Mn |
| Sep 30, 2020 | 171.47 Mn |
| Jun 30, 2020 | 107.60 Mn |
| Mar 31, 2020 | 115.89 Mn |
| Dec 31, 2019 | 123.25 Mn |
| Sep 30, 2019 | 134.00 Mn |
| Jun 30, 2019 | 122.50 Mn |
| Mar 31, 2019 | 57.19 Mn |
| Dec 31, 2018 | 74.05 Mn |
| Dec 31, 2017 | 48.75 Mn |
| Sep 30, 2017 | 114.11 Mn |
| Jun 30, 2017 | 132.55 Mn |
| Mar 31, 2017 | 121.90 Mn |
| Dec 31, 2016 | 59.47 Mn |
| Sep 30, 2016 | 106.29 Mn |
| Jun 30, 2016 | 101.84 Mn |
| Mar 31, 2016 | 95.24 Mn |
| Dec 31, 2015 | 96.31 Mn |
| Sep 30, 2015 | 102.75 Mn |
| Jun 30, 2015 | 91.81 Mn |
| Mar 31, 2015 | 82.29 Mn |
| Dec 31, 2014 | 85.68 Mn |
| Sep 30, 2014 | 77.26 Mn |
| Jun 30, 2014 | 66.30 Mn |
| Mar 31, 2014 | 67.90 Mn |
| Dec 31, 2013 | 65.39 Mn |
| Sep 30, 2013 | 25.85 Mn |
| Jun 30, 2013 | 21.53 Mn |
| Mar 31, 2013 | 20.69 Mn |
| Dec 31, 2012 | 18.09 Mn |
| Sep 30, 2012 | 16.14 Mn |
| Jun 30, 2012 | 7.86 Mn |
| Mar 31, 2012 | 7.05 Mn |
| Dec 31, 2011 | 6.88 Mn |
| Sep 30, 2011 | 3.00 Mn |
| Jun 30, 2011 | 3.62 Mn |
| Dec 31, 2010 | 1.71 Mn |